KRAS and metastatic colorectal cancer: The study observed improvements in FCSI and EQ-5D Index scores, particularly favoring the panitumumab + BSC in wild-type KRAS metastatic colorectal cancer, with early dropout rates of 38–42% for panitumumab + BSC and 68% for BSC alone.